AT335451B - PROCESS FOR PRODUCING NEW SUBSTITUTED TRIAZOLES - Google Patents

PROCESS FOR PRODUCING NEW SUBSTITUTED TRIAZOLES

Info

Publication number
AT335451B
AT335451B AT150376A AT150376A AT335451B AT 335451 B AT335451 B AT 335451B AT 150376 A AT150376 A AT 150376A AT 150376 A AT150376 A AT 150376A AT 335451 B AT335451 B AT 335451B
Authority
AT
Austria
Prior art keywords
sep
producing new
new substituted
substituted triazoles
triazoles
Prior art date
Application number
AT150376A
Other languages
German (de)
Other versions
ATA150376A (en
Original Assignee
Astra Laekemedel Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE7308365A external-priority patent/SE401833B/en
Application filed by Astra Laekemedel Ab filed Critical Astra Laekemedel Ab
Priority to AT150376A priority Critical patent/AT335451B/en
Publication of ATA150376A publication Critical patent/ATA150376A/en
Application granted granted Critical
Publication of AT335451B publication Critical patent/AT335451B/en

Links

Landscapes

  • External Artificial Organs (AREA)

Description

  

   <Desc/Clms Page number 1> 
 
 EMI1.1 
 
 EMI1.2 
 
 EMI1.3 
 
 EMI1.4 
 

 <Desc/Clms Page number 2> 

 
 EMI2.1 
 
 EMI2.2 
 
 EMI2.3 
 
 EMI2.4 
 
 EMI2.5 
 
 EMI2.6 
 
 EMI2.7 
 

 <Desc/Clms Page number 3> 

 
 EMI3.1 
 
 EMI3.2 
 
<tb> 
<tb> dieseVerbindung <SEP> R1 <SEP> R2 <SEP> R3 <SEP> R4 <SEP> Fp.

   C <SEP> Ausbeute <SEP> Analyse: <SEP> Ber. <SEP> %
<tb> Nr. <SEP> % <SEP> Gef. <SEP> %
<tb> C <SEP> H <SEP> N <SEP> Cl
<tb> 47,72 <SEP> 4,81 <SEP> 33,39 <SEP> 14,09
<tb> I <SEP> 2-CH <SEP> H <SEP> H <SEP> H <SEP> 233 <SEP> - <SEP> 34 <SEP> 97 <SEP> 47, <SEP> 7 <SEP> 4, <SEP> 9 <SEP> 33,5 <SEP> 14,0
<tb> 49, <SEP> 53 <SEP> 5, <SEP> 67 <SEP> 31, <SEP> 51 <SEP> 13, <SEP> 29 <SEP> 
<tb> II <SEP> 2-CH. <SEP> 6-CH.

   <SEP> H <SEP> H <SEP> 219 <SEP> - <SEP> 20 <SEP> 27 <SEP> 49, <SEP> 3 <SEP> 5, <SEP> 78 <SEP> 31, <SEP> 2 <SEP> 13, <SEP> 1 <SEP> 
<tb> 51, <SEP> 33 <SEP> 6, <SEP> 10 <SEP> 29, <SEP> 93 <SEP> 12, <SEP> 63 <SEP> 
<tb> m <SEP> 2-Ch3 <SEP> 4-CH3 <SEP> 6-CH3 <SEP> H <SEP> 218-19 <SEP> 57 <SEP> 51,2 <SEP> 6,3 <SEP> 29,4 <SEP> 12,7
<tb> 39, <SEP> 58 <SEP> 3, <SEP> 69 <SEP> 30, <SEP> 77 <SEP> 25, <SEP> 96 <SEP> 
<tb> IV <SEP> 2-Cl <SEP> H <SEP> H <SEP> H <SEP> 249 <SEP> - <SEP> 50 <SEP> 92 <SEP> 39, <SEP> 5 <SEP> 3, <SEP> 70 <SEP> 30, <SEP> 4 <SEP> 25, <SEP> 8 <SEP> 
<tb> 35, <SEP> 14 <SEP> 2, <SEP> 95 <SEP> 27, <SEP> 33 <SEP> 34, <SEP> 58 <SEP> 
<tb> V <SEP> 2-Cl <SEP> 4-Cl <SEP> H <SEP> H <SEP> 270 <SEP> - <SEP> 71 <SEP> 89 <SEP> 35, <SEP> 4 <SEP> 2, <SEP> 94 <SEP> 27, <SEP> 1 <SEP> 34, <SEP> 6 <SEP> 
<tb> 35, <SEP> 14 <SEP> 2, <SEP> 95 <SEP> 27, <SEP> 33 <SEP> 34,

   <SEP> 58 <SEP> 
<tb> VI <SEP> 2-Cl <SEP> 6-Cl <SEP> H <SEP> H <SEP> 219 <SEP> - <SEP> 20 <SEP> 83 <SEP> 34, <SEP> 8 <SEP> 3, <SEP> 05 <SEP> 27, <SEP> 3 <SEP> 34, <SEP> 4 <SEP> 
<tb> 39, <SEP> 36 <SEP> 3, <SEP> 90 <SEP> 25, <SEP> 04 <SEP> 31, <SEP> 69 <SEP> 
<tb> VII <SEP> 2-Cl <SEP> 6-Cl <SEP> H <SEP> H <SEP> 224 <SEP> - <SEP> 25 <SEP> 56 <SEP> 39, <SEP> 4 <SEP> 3, <SEP> 96 <SEP> 25,1 <SEP> 31,4
<tb> 
 

 <Desc/Clms Page number 4> 

 
 EMI4.1 
 
 EMI4.2 
 
 EMI4.3 
 
 EMI4.4 
 
 EMI4.5 
 

 <Desc/Clms Page number 5> 

 
 EMI5.1 
 
 EMI5.2 
 
<tb> 
<tb> :

  FLA <SEP> 136 <SEP> Wy-8678
<tb> (mg/kg) <SEP> (mg/kg)
<tb> Minimale <SEP> tägliche <SEP> Dosis <SEP> mit <SEP> antihypertonisehen <SEP> Wirkungen, <SEP> bestimmt <SEP> als <SEP> die <SEP> Dosis,
<tb> die <SEP> den <SEP> mittleren <SEP> arteriellen <SEP> Blutdruck <SEP> um
<tb> mehr <SEP> als <SEP> 15 <SEP> mm <SEP> Hg <SEP> bei <SEP> nicht <SEP> anästhesierten <SEP> 
<tb> Nieren-hypertonischen <SEP> Ratten <SEP> reduzierte <SEP> 2,5 <SEP> -5 <SEP> 2,5
<tb> Akute <SEP> Toxizität <SEP> bei <SEP> Mäusen <SEP> (LD50 <SEP> i.

   <SEP> p.) <SEP> 340 <SEP> 70
<tb> Die <SEP> intraperitoneale <SEP> Dosis, <SEP> welche <SEP> die <SEP> spontane
<tb> motorische <SEP> Aktivität <SEP> von <SEP> Mäusen <SEP> auf <SEP> 50%
<tb> der <SEP> Kontrollwerte <SEP> reduzierte
<tb> a) <SEP> Messungen <SEP> 1 <SEP> h <SEP> nach <SEP> Verabreichung <SEP> 90 <SEP> 3
<tb> b) <SEP> Messungen <SEP> 3 <SEP> h <SEP> nach <SEP> Verabreichung <SEP> 170 <SEP> 3
<tb> 




   <Desc / Clms Page number 1>
 
 EMI1.1
 
 EMI1.2
 
 EMI1.3
 
 EMI1.4
 

 <Desc / Clms Page number 2>

 
 EMI2.1
 
 EMI2.2
 
 EMI2.3
 
 EMI2.4
 
 EMI2.5
 
 EMI2.6
 
 EMI2.7
 

 <Desc / Clms Page number 3>

 
 EMI3.1
 
 EMI3.2
 
<tb>
<tb> this connection <SEP> R1 <SEP> R2 <SEP> R3 <SEP> R4 <SEP> Fp.

   C <SEP> yield <SEP> analysis: <SEP> calc. <SEP>%
<tb> No. <SEP>% <SEP> Found <SEP>%
<tb> C <SEP> H <SEP> N <SEP> Cl
<tb> 47.72 <SEP> 4.81 <SEP> 33.39 <SEP> 14.09
<tb> I <SEP> 2-CH <SEP> H <SEP> H <SEP> H <SEP> 233 <SEP> - <SEP> 34 <SEP> 97 <SEP> 47, <SEP> 7 <SEP> 4, <SEP> 9 <SEP> 33.5 <SEP> 14.0
<tb> 49, <SEP> 53 <SEP> 5, <SEP> 67 <SEP> 31, <SEP> 51 <SEP> 13, <SEP> 29 <SEP>
<tb> II <SEP> 2-CH. <SEP> 6-CH.

   <SEP> H <SEP> H <SEP> 219 <SEP> - <SEP> 20 <SEP> 27 <SEP> 49, <SEP> 3 <SEP> 5, <SEP> 78 <SEP> 31, <SEP> 2 <SEP> 13, <SEP> 1 <SEP>
<tb> 51, <SEP> 33 <SEP> 6, <SEP> 10 <SEP> 29, <SEP> 93 <SEP> 12, <SEP> 63 <SEP>
<tb> m <SEP> 2-Ch3 <SEP> 4-CH3 <SEP> 6-CH3 <SEP> H <SEP> 218-19 <SEP> 57 <SEP> 51.2 <SEP> 6.3 <SEP > 29.4 <SEP> 12.7
<tb> 39, <SEP> 58 <SEP> 3, <SEP> 69 <SEP> 30, <SEP> 77 <SEP> 25, <SEP> 96 <SEP>
<tb> IV <SEP> 2-Cl <SEP> H <SEP> H <SEP> H <SEP> 249 <SEP> - <SEP> 50 <SEP> 92 <SEP> 39, <SEP> 5 <SEP> 3, <SEP> 70 <SEP> 30, <SEP> 4 <SEP> 25, <SEP> 8 <SEP>
<tb> 35, <SEP> 14 <SEP> 2, <SEP> 95 <SEP> 27, <SEP> 33 <SEP> 34, <SEP> 58 <SEP>
<tb> V <SEP> 2-Cl <SEP> 4-Cl <SEP> H <SEP> H <SEP> 270 <SEP> - <SEP> 71 <SEP> 89 <SEP> 35, <SEP> 4 < SEP> 2, <SEP> 94 <SEP> 27, <SEP> 1 <SEP> 34, <SEP> 6 <SEP>
<tb> 35, <SEP> 14 <SEP> 2, <SEP> 95 <SEP> 27, <SEP> 33 <SEP> 34,

   <SEP> 58 <SEP>
<tb> VI <SEP> 2-Cl <SEP> 6-Cl <SEP> H <SEP> H <SEP> 219 <SEP> - <SEP> 20 <SEP> 83 <SEP> 34, <SEP> 8 < SEP> 3, <SEP> 05 <SEP> 27, <SEP> 3 <SEP> 34, <SEP> 4 <SEP>
<tb> 39, <SEP> 36 <SEP> 3, <SEP> 90 <SEP> 25, <SEP> 04 <SEP> 31, <SEP> 69 <SEP>
<tb> VII <SEP> 2-Cl <SEP> 6-Cl <SEP> H <SEP> H <SEP> 224 <SEP> - <SEP> 25 <SEP> 56 <SEP> 39, <SEP> 4 < SEP> 3, <SEP> 96 <SEP> 25.1 <SEP> 31.4
<tb>
 

 <Desc / Clms Page number 4>

 
 EMI4.1
 
 EMI4.2
 
 EMI4.3
 
 EMI4.4
 
 EMI4.5
 

 <Desc / Clms Page number 5>

 
 EMI5.1
 
 EMI5.2
 
<tb>
<tb>:

  FLA <SEP> 136 <SEP> Wy-8678
<tb> (mg / kg) <SEP> (mg / kg)
<tb> Minimum <SEP> daily <SEP> dose <SEP> with <SEP> antihypertensive <SEP> effects, <SEP> determines <SEP> as <SEP> the <SEP> dose,
<tb> the <SEP> the <SEP> mean <SEP> arterial <SEP> blood pressure <SEP>
<tb> more <SEP> than <SEP> 15 <SEP> mm <SEP> Hg <SEP> for <SEP> not <SEP> anesthetized <SEP>
<tb> Kidney-hypertonic <SEP> rats <SEP> reduced <SEP> 2.5 <SEP> -5 <SEP> 2.5
<tb> Acute <SEP> toxicity <SEP> in <SEP> mice <SEP> (LD50 <SEP> i.

   <SEP> p.) <SEP> 340 <SEP> 70
<tb> The <SEP> intraperitoneal <SEP> dose, <SEP> which <SEP> the <SEP> spontaneous
<tb> motor <SEP> activity <SEP> of <SEP> mice <SEP> to <SEP> 50%
<tb> the <SEP> control values <SEP> reduced
<tb> a) <SEP> measurements <SEP> 1 <SEP> h <SEP> after <SEP> administration <SEP> 90 <SEP> 3
<tb> b) <SEP> measurements <SEP> 3 <SEP> h <SEP> after <SEP> administration <SEP> 170 <SEP> 3
<tb>

Claims (1)

EMI5.3 EMI5.4 EMI5.5 EMI5.6 EMI5.7 EMI5.8 <Desc/Clms Page number 6> EMI6.1 EMI5.3 EMI5.4 EMI5.5 EMI5.6 EMI5.7 EMI5.8 <Desc / Clms Page number 6> EMI6.1
AT150376A 1973-06-14 1976-03-01 PROCESS FOR PRODUCING NEW SUBSTITUTED TRIAZOLES AT335451B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT150376A AT335451B (en) 1973-06-14 1976-03-01 PROCESS FOR PRODUCING NEW SUBSTITUTED TRIAZOLES

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE7308365A SE401833B (en) 1973-06-14 1973-06-14 PROCEDURE FOR PREPARING CERTAIN STATEMENTS 1,2,4-FRIAZOLE DERIVATIVES
AT471974A AT333274B (en) 1973-06-14 1974-06-07 PROCESS FOR PRODUCING NEW SUBSTITUTED TRIAZOLES
AT150376A AT335451B (en) 1973-06-14 1976-03-01 PROCESS FOR PRODUCING NEW SUBSTITUTED TRIAZOLES

Publications (2)

Publication Number Publication Date
ATA150376A ATA150376A (en) 1976-07-15
AT335451B true AT335451B (en) 1977-03-10

Family

ID=27147585

Family Applications (1)

Application Number Title Priority Date Filing Date
AT150376A AT335451B (en) 1973-06-14 1976-03-01 PROCESS FOR PRODUCING NEW SUBSTITUTED TRIAZOLES

Country Status (1)

Country Link
AT (1) AT335451B (en)

Also Published As

Publication number Publication date
ATA150376A (en) 1976-07-15

Similar Documents

Publication Publication Date Title
DE1795587A1 (en) New nitroso compounds and processes for their preparation
AT327174B (en) PROCESS FOR THE PRODUCTION OF NEW SULPHAMIDES AND THEIR ACID ADDITION SALTS
AT335451B (en) PROCESS FOR PRODUCING NEW SUBSTITUTED TRIAZOLES
EP0054873B1 (en) 3,4-di-substituted 1,2,5-oxadiazole-2 oxides, method for their preparation and pharmaceutical compositions containing them
EP0000727B1 (en) 3-(4-(1,3-diazacycloalkene-2-yl)-phenyl)-1,2-benzisothiazoles, process for their preparation and medicaments containing them.
AT347471B (en) PROCESS FOR THE PREPARATION OF NEW QUINOXALINE-1,4-DIOXIDE DERIVATIVES
DE1210883B (en) Process for the preparation of derivatives of 7-oxycoumarin
AT220616B (en) Process for the preparation of new hydrazine derivatives and their acidic salts
AT203504B (en) Process for the preparation of new derivatives of piperazine
AT339276B (en) PROCESS FOR THE PREPARATION OF BASIC CYCLOAL CANONOXIMATHERS AND THEIR ACID ADDITION SALTS
AT335448B (en) PROCESS FOR THE PREPARATION OF NEW IMIDAZOLE DERIVATIVES AND THEIR SALTS
AT339320B (en) PROCESS FOR THE PREPARATION OF NEW PIPERAZINE DERIVATIVES AND THEIR SALT
AT217462B (en) Process for the preparation of the new 1- (2&#39;-hydroxyethyl) -3- (5-nitrofurfurylidene-amino) -imidazolidin-thione- (2)
AT275542B (en) Process for the preparation of new arylsulfonylsemicarbazides
AT315843B (en) Process for the preparation of new ethylene diamine derivatives
AT288394B (en) Process for the preparation of new cinnamic acid amides
AT229864B (en) Process for the preparation of the new 3- (2-cyanoethyl) -1- (5-nitrofurfurylidene-amino) -hydantoin
AT303712B (en) Process for the preparation of the new 2,2&#39;-dihydroxydinaphthyl-1,1&#39;-diglyzidäthers
AT335423B (en) METHOD OF PREPARING THE NEW (L) 1- (4&#39;-HYDROXYPHENOXY) -2-HYDROXY-3-ISOPROPYLAMINO-PROPANE AND ITS ACID ADDITION SALT
AT231452B (en) Process for the preparation of new, racemic or optically active 1- (p-chlorophenyl- [pyridyl- (2 &#39;)] -methyl) -4-hydroxyethoxyethyl-piperazine
AT330747B (en) PROCESS FOR THE PREPARATION OF NEW 1- CYANOPHENOXY-2-HYDROXY-3-PROPARGYLAMINOPROPANES AND THEIR ACID ADDITION SALTS
AT347927B (en) PROCESS FOR THE PREPARATION OF NEW 3-CYANAMINO-4-TRIFLUOROMETHYL-2,6-DINITROANILINES
AT331232B (en) PROCESS FOR THE PRODUCTION OF NEW 3-ALCOXY-5-SUBST.PHENYL ACIDIC ACIDS
AT282633B (en) PROCESS FOR PREPARING NEW CINNAMID AMIDES
SU622401A3 (en) Method of producing salts of 1,2-dimethyl-3,5-diphenyl pirazolium

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee
REN Ceased due to non-payment of the annual fee